Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer

Overexpression of insulin growth factor receptor type 1 (IGF-1R) is observed in many cancers. Antibody drug conjugates (ADCs) with PEGylated maytansine (PEG(6)-DM1) show promise in vitro. We developed PEG(6)-DM1 ADCs with low and high drug to antibody ratios (DAR) using an anti-IGF-1R antibody cixut...

Descripción completa

Detalles Bibliográficos
Autores principales: Solomon, Viswas Raja, Alizadeh, Elahe, Bernhard, Wendy, Makhlouf, Amal, Hartimath, Siddesh V., Hill, Wayne, El-Sayed, Ayman, Barreto, Kris, Geyer, Clarence Ronald, Fonge, Humphrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596529/
https://www.ncbi.nlm.nih.gov/pubmed/33122707
http://dx.doi.org/10.1038/s41598-020-75279-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596529/
https://www.ncbi.nlm.nih.gov/pubmed/33122707
http://dx.doi.org/10.1038/s41598-020-75279-z

Ejemplares similares